Skip to main content

Table 1 PICOS criteria and Cochrane Risk of bias in included Trails

From: Safety, efficacy and biomarkers analysis of mesenchymal stromal cells therapy in ARDS: a systematic review and meta-analysis based on phase I and II RCTs

Population Interventions Comparators Outcomes Study types
PICOS criteria
Patients with Berlin criteria-defined ARDS, Age > 18 years, not animals MSCs/MSC, Progenitor cell, mesenchymal stem cell, mesenchymal stromal cell, stem cell Placebo Subjects with Adverse events (AEs), subjects with Serious Adverse events (SAEs), mortality, PaO2/FiO2, Biomarkers randomized controlled trials (RCT), blind or not
Trails Randomization method Allocation concealment Blinding Incomplete outcome data Selective reporting Other bias
Participants and personnel Assessment
Cochrane Risk of bias in included Trails
Monsel et al. [22] Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Bellingan et al. [21] Low risk Low risk Unclear risk Unclear risk Low risk Low risk High risk
Lanzoni et al. [20] Low risk Unclear risk Unclear risk Unclear risk Low risk Low risk Low risk
Matthay et al. [19] Low risk Low risk Unclear risk Unclear risk Low risk Low risk High risk
Zheng et al. [18] Unclear risk Unclear risk Unclear risk Unclear risk Low risk Low risk Low risk